Cullgen

Anji Pharma operates as a subsidiary of Cullgen, created to independently advance select clinical-stage programs, particularly those with near-term regulatory pathways. This structure allows the parent company to maintain focus on its preclinical degradation pipeline while enabling Anji Pharma to pursue a separate development and financing strategy. The arrangement is unusual among early-stage protein-degradation biotechs and reflects a modular approach to managing platform risk versus clinical attrition risk.

Cullgen prioritizes oncology as its lead therapeutic area, with additional programs in inflammatory and immune-mediated diseases. The company has not publicly disclosed a full target list, but its Astellas Pharma partnership focuses on immuno-oncology applications of targeted protein degradation. The firm’s public statements indicate an emphasis on historically undruggable intracellular targets, the same class that attracted large pharma interest to the degradation modality broadly.

Cullgen competes with larger, US-headquartered protein-degradation companies such as Arvinas and Kymera Therapeutics, both of which are publicly traded and have clinical-stage assets. Cullgen’s differentiation rests on its Asian R&D footprint, its uSMITE platform’s screening approach to novel E3 ligases, and its subsidiary model via Anji Pharma. The firm’s competitive challenge is a narrower resource base relative to well-capitalized peers, making its reverse-merger public listing a consequential step for future head-to-head development timelines.